空隙
发表于 2025-3-21 19:46:45
http://impactfactor.cn/if/?ISSN=BK0321063http://impactfactor.cn/ifr/?ISSN=BK0321063http://impactfactor.cn/at/?ISSN=BK0321063http://impactfactor.cn/atr/?ISSN=BK0321063http://impactfactor.cn/tc/?ISSN=BK0321063http://impactfactor.cn/tcr/?ISSN=BK0321063http://impactfactor.cn/ii/?ISSN=BK0321063http://impactfactor.cn/iir/?ISSN=BK0321063http://impactfactor.cn/5y/?ISSN=BK0321063http://impactfactor.cn/5yr/?ISSN=BK0321063
智力高
发表于 2025-3-21 23:22:43
neue betriebswirtschaftliche forschung (nbf)ase. Defects in RNA splicing account for at least 10% of all genetic disorders, with the number expected to increase as more information is uncovered on the contribution of noncoding genomic regions to disease. Splice modulation through the use of antisense oligonucleotides (AOs) has emerged as a pr
mitten
发表于 2025-3-22 03:47:26
Zusammenfassung, Implikationen und Ausblick,proach uses antisense oligonucleotides (AON) to modify the splicing of pre-mRNA to correct the mutation responsible for a disease, or to suppress a particular gene expression, as in allergic diseases. Antisense-mediated exon skipping is most extensively studied in Duchenne muscular dystrophy (DMD) a
spondylosis
发表于 2025-3-22 06:26:34
http://reply.papertrans.cn/33/3211/321063/321063_4.png
CHOP
发表于 2025-3-22 09:12:40
https://doi.org/10.1007/978-3-663-13267-7ss of motor neurons. With the discovery of the intronic splicing silencer N1 (ISS-N1) as a potential target for antisense therapy, several antisense oligonucleotides (ASOs) are being developed to include exon 7 in the final mRNA transcript of the . gene and thereby increasing the production of spina
倔强不能
发表于 2025-3-22 13:20:18
http://reply.papertrans.cn/33/3211/321063/321063_6.png
倔强不能
发表于 2025-3-22 17:53:27
http://reply.papertrans.cn/33/3211/321063/321063_7.png
控制
发表于 2025-3-22 23:11:51
,Einteilungen der Kapsel-Band-Läsionen,trophy (DMD). While we now have a number of AO drug candidates in clinical trials, we are still faced with issues of poor or controversial efficacy in some of these drugs. This is the case with eteplirsen, an exon 51-skipping AO that is the first and only FDA-approved drug for DMD to date. Effective
Soliloquy
发表于 2025-3-23 03:27:46
http://reply.papertrans.cn/33/3211/321063/321063_9.png
SAGE
发表于 2025-3-23 08:07:48
http://reply.papertrans.cn/33/3211/321063/321063_10.png